Italian survey on managing immune checkpoint inhibitors in oncology during COVID‐19 outbreak

Abstract

Background: During COVID-19 outbreak, oncological care has been reorganized. Patients with cancer have been reported to experience a more severe COVID-19 syndrome; moreover, there are concerns of a potential interference between immune checkpoint inhibitors (ICIs) and SARS-CoV-2 pathogenesis. Materials and methods: Between 6 and 16 May 2020, a 22-item survey was sent to Italian physicians involved in administering ICIs. It aimed at exploring the perception about SARS-CoV-2-related risks in cancer patients receiving ICIs, and the attitudes towards their management. Results: The 104 respondents had a median age of 35.5 years, 58.7% were females and 71.2% worked in Northern Italy. 47.1% of respondents argued a synergism between ICIs and SARS-CoV-2 pathogenesis leading to worse outcomes, but 97.1% would not deny an ICI only for the risk of infection. During COVID-19 outbreak, to reduce hospital visits, 55.8% and 30.8% opted for the highest labelled dose of each ICI and/or, among different ICIs for the same indication, for the one with the longer interval between cycles, respectively. 53.8% of respondents suggested testing for SARS-CoV-2 every cancer patient candidate to ICIs. 71.2% declared to manage patients with onset of dyspnoea and cough as infected by SARS-CoV-2 until otherwise proven; however, 96.2% did not reduce the use of steroids to manage immune-related toxicities. The administration of ICIs in specific situations for different cancer types has not been drastically conditioned. Conclusions: These results highlight the uncertainties around the perception of a potential interference between ICIs and COVID-19, supporting the need of focused studies on this topic.

SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic

“…[25][26][27] The majority of those guidelines/surveys advocate for treatment modifications such as extending the cycles of immunotherapy administrations, simplification of radiotherapy duration or implementing telemedicine procedures. [27][28][29][30] However, the importance of regular testing of both oncological HCP and patients with cancer is rarely stressed.…”

Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months

“…There could be increased protocol deviations as patients miss hospital visits, as well as delayed data reporting, potentially impacting patient safety. Of particular concern are immunotherapy trials, where fever and pneumonitis are expected complications of therapy [39] and might be difficult to discern from symptoms of COVID-19.…”

Cancer Patient Management Strategy in a Cancer Center of Zhejiang, China During the COVID-19 Pandemic 

“…Our screening strategy relied on the adequate laboratory testing capacity, which brought high work load to the clinical laboratory staff. Other cancer centers suggested to test cancer patients with active therapy only [26], which could reduce the sample volume for the clinical laboratory, but we suggested additional prevention method must be strictly used to prevent in-hospital transmission by outpatients and patients' companions, especially in region with a high incidence of SARS-CoV-2 infection.…”